Clinical Trial Detail

NCT ID NCT03775850
Title A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Evelo Biosciences, Inc.
Indications

Advanced Solid Tumor

urinary bladder cancer

colorectal cancer

lung non-small cell carcinoma

gastroesophageal cancer

triple-receptor negative breast cancer

renal cell carcinoma

Therapies

EDP1503

EDP1503 + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST